Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateEcosystem ConnectDistinguished InvestigatorsGlobal ConferencesRLT EducationRLT ComponentsSponsorsTrial Stats
A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Description:
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Sponsor:
OranomedContacts:
Jason D Hurt, MDjason.hurt@oranomed.com
4696380744
Government Study Link:
NCT05283330 - Click here to see study onClinicalTrials.gov
²¹²Pb-DOTAM-GRPR1
Isotope(s):
Target(s):
- GRPR
Chelator: DOTAM
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Not yet provided. Contact Jason D Hurt, MD for more information.
4696380744
jason.hurt@oranomed.com
